Drug Trial Radar · NCT02719574
Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation
Last checked: Nov 20, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
336
Actual
Start
Apr 30, 2016
Primary completion
Dec 28, 2023
Study completion Jan 24, 2024
Sponsor
- Lead sponsor
- Forma Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 25, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 (olutasidenib) as a single agent or in combination with azacitidine or cytarabine. The Phase 1 stage of the study is split into 2 distinct parts: a dose escalation part, which will utilize an open-label design of FT-2102 (olutasidenib) (single agent) and FT-2102 (olutasidenib) + azacitidine (combination agent) administered via one or more intermittent dosing schedules followed by a dose expansion part. The dose expansion part will enroll patients in up to 5 expansion cohorts, exploring single-agent FT-2102 (olutasidenib) activity as well as combination activity with azacitidine or cytarabine. Following the completion of the relevant Phase 1 cohorts, Phase 2 will begin enrollment. Patients will be enrolled across 8 different cohorts, examining the effect of FT-2102 (olutasidenib) (as a single agent) and FT-2102 (olutasidenib) + azacitidine (combination) on various AML/MDS disease states.
Conditions
- Acute Myeloid Leukemia
- Acute Myelogenous Leukemia
- Myelodysplastic Syndrome
Interventions
FT-2102 (olutasidenib)Drug
FT-2102 (olutasidenib) will be supplied as 50 mg or 150 mg capsules and will be administered per the protocol defined frequency and dose level
AzacitidineDrug
azacitidine will be administered per site's standard of care
CytarabineDrug
low-dose cytarabine will be administered per site's standard of care
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Phase 1: From start of drug administration (Day 1) up to 28 days after last dose of study drug (up to 82 months)
- Phase 1: Number of Participants With Change From Baseline in Clinically Significant Abnormal Laboratory ValuesTime frame: Phase 1: From Baseline up to 28 days after last dose of study drug (up to 82 months)
- Phase 1: Number of Participants With Change From Baseline in Clinically Significant Abnormal Electrocardiogram (ECG)Time frame: Phase 1: From Baseline up to 28 days after last dose of study drug (up to 82 months)
- Phase 2, Cohort 1: Percentage of Participants With Complete Remission (CR) Plus Complete Remission With Partial Hematological Recovery (CRh) for Acute Myeloid Leukemia Assessed by Investigator Based on International Working Group (IWG) Response CriteriaTime frame: Phase 2: up to 3 weeks post last dose of study drug or until the introduction of new anticancer therapy, whichever is earlier (up to 82 months)
- Phase 2, Cohort 3, 4, 5, 6, 7, 8: Percentage of Participants With CR Plus CRh for Acute Myeloid Leukemia Assessed by Investigator Based on IWG Response CriteriaTime frame: Phase 2: up to 3 weeks post last dose of study drug or until the introduction of new anticancer therapy, whichever is earlier (up to 82 months)
- Phase 2, Cohort 4 and 5: Percentage of Participants With CR for MDS Assessed by IWG Response CriteriaTime frame: Phase 2: up to 3 weeks post last dose of study drug or until the introduction of new anticancer therapy, whichever is earlier (up to 82 months)
- Phase 2, Cohort 2: Four-month Relapse Free Survival (RFS) RateTime frame: Phase 2: From the date of first dose until relapse or death from any cause, whichever occurs first (up to 4 months)
Locations
60 sites in 9 countries. Site status is shown where the registry gives one.
UCLA Medical Center
Los Angeles, California
UC Davis Comprehensive Cancer Center
Sacramento, California
Yale University
New Haven, Connecticut
University of Miami
Miami, Florida
Emory Winship Cancer Institute
Atlanta, Georgia
Northwestern University Feinberg School of Medicine
Chicago, Illinois
University of Maryland Greenebaum Cancer Center
Baltimore, Maryland
Karmanos Cancer Institute
Detroit, Michigan
Roswell Park Cancer Institute
Buffalo, New York
New York Medical College
Hawthorne, New York
Columbia University Medical Center
New York, New York
Cornell University Weill Medical College
New York, New York
Duke University Medical Center
Durham, North Carolina
The Ohio State University
Columbus, Ohio
Oregon Health & Science University
Portland, Oregon
Sarah Cannon Research Institute - Tennessee Oncology
Nashville, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee
University of Texas Southwestern Medical Center
Dallas, Texas
MD Anderson Cancer Center
Houston, Texas
Box Hill Hospital, Monash University and Eastern Health Clinical School
Box Hill, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Victoria Cancer Care Center
Parkville, Victoria, Australia
Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia
Princess Margaret Hospital
Toronto, Ontario, Canada
Service d'Hématologie Clinique, Hôpital Avicenne-APHP-Université Paris
Bobigny, France
Assistance Publique Hopitaux de Marseille (AP-HM) - Hopital Nord
Marseille, France
Centre Hospitalier Universitaire Nantes
Nantes, France
Hôpital Saint-Louis
Paris, France
Hopitaux Universitaires Est Parisien Hopital Saint-Antoine
Paris, France
Centre Hospitalier Universitaire (CHU) Bordeaux - Hospitaux du Haut Leveque
Pessac, France
Centre Hospitalier Lyon Sud
Pierre-Bénite, France
University Hospital of Rennes
Rennes, France
Institut Universitaire du Cancer Toulouse - Oncopole
Toulouse, France
Centre Hospitalier Universitaire de Nancy - Hopital Brabois
Vandœuvre-lès-Nancy, France
Institut de Cancérologie Gustave Roussy
Villejuif, France
Staedtisches Klinikum Braunschweig gGmbH
Braunschweig, Germany
Universitaetsklinikum Giessen und Marburg GmbH - Klinik fuer Innere Medizin
Giessen, Germany
Landeszentrum fuer Zell- und Gentherapie
Halle, Germany
Universitätsklinikum Münster Medizinische Klinik A, Hämatologie, Hämostaseologi
Münster, Germany
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.